Jérémie Sellam1, Anne-Christine Rat2, Soraya Fellahi3, Jean-Philippe Bastard4, Willy Ngueyon Sime5, Hang Korng Ea6, Xavier Chevalier7, Pascal Richette6, Jacqueline Capeau8, Francis Guillemin5, Francis Berenbaum9. 1. Hôpitaux de Paris (AP-HP), Rheumatology department, Saint-Antoine Hospital, DMU 3iD, 184 rue du Faubourg Saint-Antoine, Paris 75012, France; Sorbonne Université, 15-21 Rue de l'École de Médecine, Paris 75006, France; Inserm UMRS_938, CRSA, 19 Rue de Chaligny, Paris 75012, France. Electronic address: jeremie.sellam@aphp.fr. 2. Inserm CIC 1433 CHRU de Nancy, Université de Lorraine, Hôpitaux de Brabois, Allée du Morvan, Vandoeuvre-lès-Nancy 54500, France; Université de Lorraine, EA 4360, APEMAC, 9 avenue de la Forêt de Haye, BP20199, Vandoeuvre-lès-Nancy 54505, France; Université de Caen Normandie, UMR-S 1075, 2 rue des Rochambelles, Caen cedex 5 14032, France; Rheumatology department, CHU de Caen, Avenue de la Côte de Nacre, Caen 14000, France. 3. Sorbonne Université, 15-21 Rue de l'École de Médecine, Paris 75006, France; Inserm UMRS_938, CRSA, 19 Rue de Chaligny, Paris 75012, France; AP-HP, Hôpital Tenon, Service de Biochimie et Hormonologie, UF Bio-marqueurs inflammatoires et métaboliques, 1 rue de la Chine, Paris 75020, France. 4. Sorbonne Université, 15-21 Rue de l'École de Médecine, Paris 75006, France; Inserm UMRS_938, CRSA, 19 Rue de Chaligny, Paris 75012, France; AP-HP, Hôpital Tenon, Service de Biochimie et Hormonologie, UF Bio-marqueurs inflammatoires et métaboliques, 1 rue de la Chine, Paris 75020, France; AP-HP, Hôpitaux Universitaires Henri Mondor, Département de Biochimie-Pharmacologie-Biologie Moléculaire-Génétique Médicale, 51 Avenue du Maréchal de Lattre de Tassigny, Créteil 94010, France. 5. Inserm CIC 1433 CHRU de Nancy, Université de Lorraine, Hôpitaux de Brabois, Allée du Morvan, Vandoeuvre-lès-Nancy 54500, France; Université de Lorraine, EA 4360, APEMAC, 9 avenue de la Forêt de Haye, BP20199, Vandoeuvre-lès-Nancy 54505, France. 6. Rheumatology department, DMU locomotion, Lariboisière Hospital, AP-HP, 2 rue Ambroise Paré, Paris 75010, France; Inserm U1132, Paris University, 2 rue Mabroise Paré, Paris 75010, France. 7. AP-HP, Hôpitaux Universitaires Henri Mondor, Rheumatology department, Paris 12 University UPEC, 51 Avenue du Maréchal de Lattre de Tassigny, Créteil 94010, France. 8. Sorbonne Université, 15-21 Rue de l'École de Médecine, Paris 75006, France; Inserm UMRS_938, CRSA, 19 Rue de Chaligny, Paris 75012, France. 9. Hôpitaux de Paris (AP-HP), Rheumatology department, Saint-Antoine Hospital, DMU 3iD, 184 rue du Faubourg Saint-Antoine, Paris 75012, France; Sorbonne Université, 15-21 Rue de l'École de Médecine, Paris 75006, France; Inserm UMRS_938, CRSA, 19 Rue de Chaligny, Paris 75012, France.
Abstract
BACKGROUND: Considering the role of metabolic diseases in osteoarthritis (OA), we investigated whether biomarkers of adipose tissue dysfunction could be associated with OA-related pain. DESIGN: We cross-sectionally analyzed patients with knee and/or hip OA at inclusion in the KHOALA cohort. We used visual analogic scale (VAS) for pain, the Western Ontario and McMaster Universities Arthritis Index (WOMAC) and Osteoarthritis Knee and Hip Quality of Life (OAKHQOL) pain subscores. At inclusion, we measured ultra-sensitive CRP (usCRP), leptin and adiponectin for calculation of leptin:adiponectin ratio (LAR), a marker of adipose tissue dysfunction associated with central adiposity, high-molecular-weight adiponectin, visfatin and apolipoproteins. Univariate and multivariable analyses using stepwise linear regression models were performed to search for correlation between pain assessments and these biomarkers, with systematic adjustment on age. RESULTS: In 596 women with hip and/or knee OA, multivariable analyses indicated that higher pain intensity was associated with higher LAR (VAS pain: β=0.49; p = 0.0001, OAKHQOL pain: β=-0.46; p = 0.0002, WOMAC pain: β=0.30; p = 0.001) in the whole group as well as in hip or knee OA patients considered separately. Pain intensity correlated also with usCRP level (VAS pain: β= 0.27; p = 0.02, OAKHQOL pain: β =-0.30; p = 0.01) and Kellgren-Lawrence score. In 267 men, no correlation between biomarkers and pain was found. CONCLUSION: Serum LAR and usCRP level are associated with pain level, independently of radiographic structural severity in women with hip and/or knee OA, emphasizing the role of adipose tissue dysfunction and of meta-inflammation in pain experience in the female population.
BACKGROUND: Considering the role of metabolic diseases in osteoarthritis (OA), we investigated whether biomarkers of adipose tissue dysfunction could be associated with OA-related pain. DESIGN: We cross-sectionally analyzed patients with knee and/or hip OA at inclusion in the KHOALA cohort. We used visual analogic scale (VAS) for pain, the Western Ontario and McMaster Universities Arthritis Index (WOMAC) and Osteoarthritis Knee and Hip Quality of Life (OAKHQOL) pain subscores. At inclusion, we measured ultra-sensitive CRP (usCRP), leptin and adiponectin for calculation of leptin:adiponectin ratio (LAR), a marker of adipose tissue dysfunction associated with central adiposity, high-molecular-weight adiponectin, visfatin and apolipoproteins. Univariate and multivariable analyses using stepwise linear regression models were performed to search for correlation between pain assessments and these biomarkers, with systematic adjustment on age. RESULTS: In 596 women with hip and/or knee OA, multivariable analyses indicated that higher pain intensity was associated with higher LAR (VAS pain: β=0.49; p = 0.0001, OAKHQOL pain: β=-0.46; p = 0.0002, WOMAC pain: β=0.30; p = 0.001) in the whole group as well as in hip or knee OA patients considered separately. Pain intensity correlated also with usCRP level (VAS pain: β= 0.27; p = 0.02, OAKHQOL pain: β =-0.30; p = 0.01) and Kellgren-Lawrence score. In 267 men, no correlation between biomarkers and pain was found. CONCLUSION: Serum LAR and usCRP level are associated with pain level, independently of radiographic structural severity in women with hip and/or knee OA, emphasizing the role of adipose tissue dysfunction and of meta-inflammation in pain experience in the female population.
Authors: Marthe Gløersen; Pernille Steen Pettersen; Tuhina Neogi; S Reza Jafarzadeh; Maria Vistnes; Christian S Thudium; Anne-Christine Bay-Jensen; Joe Sexton; Tore K Kvien; Hilde B Hammer; Ida K Haugen Journal: Arthritis Rheumatol Date: 2022-03-23 Impact factor: 15.483